Meet the VERAXA team at AACR 2026
Our team is looking forward to this year's American Association for Cancer Research (AACR) Annual Meeting 2026, where we will present preclinical in vitro and in vivo data on two of our pipeline programs and share additional insights on the capabilities of our novel Bi-Targeted Tumor-Associated Cytotoxicity (BiTAC) technology platform. Feel free to reach out to Dr. Christoph Erkel, VP Research & Development, Dr. Steffen Runz, Director Bispecific ADC Programs & Target Discovery, and Dr. Steffen Dickopf, Senior Director Immuno-Oncology, to arrange a meeting at the event.
Join us at our poster sessions to learn more about pipeline programs and technology platform:
Session PO.IM01.16 - T Cell Engagers 1
1634 / 26 - A conditionally-active, dual-targeting BiTAC TCE with superior tumor selectivity for the treatment of solid tumors
April 20, 2026, 9:00 AM - 12:00 PM local time - Section 10
Session PO.ET01.01 - Engineering the Next Wave of Antibody-Based Cancer Therapeutics
1762 / 7 - An avidity-driven, dual-targeting ADC with superior tumor selectivity for the treatment of solid tumors
April 20, 2026, 9:00 AM - 12:00 PM local time - Section 15
Get in touch to learn more!